US FDA approved BMS Sotyktu (deucravacitinib) for moderate to severe plaque psoriasis |iPharmaCenter

Genzyme's Xenpozyme approved for Acid Sphingomyelinase Deficiency | iPharmaCenter

bluebird bio's $2.8 million gene therapy Zynteglo received FDA nod for beta-thalassemia

BMS' Breyanzi was approved for relapsed or refractory LBCL | News | FDA | iPharmacenter

Lilly's and Incyte's Olumiant approved for adults with severe alopecia areata

FDA approved two Opdivo based regimens as a 1L treatment for ESCC | FDA News | iPharmaCenter

FDA approved Kymriah for follicular lymphoma | Novartis | News | Cancer | | Updates | iPharmaCenter

CMS News | HHS | USA | Medicare, and Medicaid | Health insurance | Healthcare News

2022 FDA Drug Approvals

COVID19 drug updates | FDA EMA approved COVID19 drugs

FDA gave the nod to Pfizer's Paxlovid | Pfizer to supply 2.5 million doses of Paxlovid to the UK

~$10 bn acquisition paying off for Novartis as FDA approved Novartis' Leqvio

Myasthenia Gravis News | FDA and EMA approvals |

American College of Rheumatology (ACR) Convergence all-virtual annual meeting Updates

Despite facing criticism on handling the COVID19 situation, Tedros to continue as WHO chief

FDA approved Novartis Scembli for chronic myeloid leukemia

Biogen's Aduhelm received FDA approval for Alzheimer's disease; ICER criticized approval

CMS News | US Healthcare News | Medicare and Medicaid News |

GSK’s Jemperli received approval in Europe and the US for endometrial cancer

Gilead’s Trodelvy approved for triple-negative breast cancer in US